[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356097-105":59,"doc-detail-356097-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","il-26-driven-epigenetic-remodeling-promotes-immune-evasion-in-colorectal-cancer","IL-26-driven epigenetic remodeling promotes immune evasion in colorectal cancer","","Epigenetic remodeling in the tumor microenvironment is driven by inflammatory signals, yet the mechanisms by which immune-derived inflammation controls cancer cell epigenetics remain unclear. This article demonstrates that tumor-derived IL-26 produced by tumor-specific type 17 T cells mediates epigenetic reprogramming in colorectal cancer. IL-26 accumulates in colorectal tumors resistant to immune checkpoint blockade, enters the nucleus, binds STAT1, and forms transcriptional complexes with NF-κB and AP-1, activating chromatin marked by BRD4 and H3K27ac and inducing CXCL chemokines. The resulting neutrophil infiltration suppresses CD8+ T cell responses, promoting immune evasion and tumor progression. The findings define IL-26 as a direct driver of immune microenvironment reshaping.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/il-26-driven-epigenetic-remodeling-promotes-immune-evasion-in-colorectal-cancer/356097/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/il-26-driven-epigenetic-remodeling-promotes-immune-evasion-in-colorectal-cancer/356097.png","ImageObject",300,407,{"name":92,"@type":93},"RuangKosong","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is IL-26’s role in colorectal cancer immune evasion?","Question",{"text":112,"@type":113},"IL-26 produced by tumor-specific type 17 T cells directly reprograms cancer cell epigenetics. It drives a nuclear transcriptional mechanism that increases CXCL chemokines and promotes neutrophil infiltration while suppressing CD8+ T cell responses, enabling immune evasion.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does IL-26 act inside tumor cells mechanistically?",{"text":117,"@type":113},"IL-26 functions as a noncanonical cytokine by translocating into the nucleus of tumor cells. There it binds STAT1 and forms transcriptional complexes with NF-κB and AP-1, leading to a transcriptionally active chromatin state marked by BRD4 and H3K27ac.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is IL-26 associated with resistance to immune checkpoint blockade?",{"text":121,"@type":113},"IL-26–expressing type 17 T cells selectively accumulate in colorectal tumors that are resistant to immune checkpoint blockade therapy. This IL-26-driven pathway promotes immune-suppressive microenvironment features such as neutrophil infiltration and CD8+ T cell suppression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356097,1790653242,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},962090883219,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article [https://doi.org/10.1038/s41467-026-75754-7](https://doi.org/10.1038/s41467-026-75754-7)  \nIL-26-driven epigenetic remodeling promotes immune evasion in colorectal cancer  \nReceived: 29 January 2026  \n\n| Accepted: 12 July 2026 |\n| --- |\n| |\n| Check for updates |\n\nTakumi Itoh 1 , Ryo Hatano 1 , Yuta Hasegawa1,2, Nao Hosokawa1, Kazuyoshi Takeda 3,4,5, Ayako Yamamoto1, Yoshiya Horimoto 6,7,8, Jinghui Yu 1, Hayato Nakamura1, Harumi Saeki6, Shogo Ehata 9, Shuji Matsuoka 10, Haruna Otsuka1, Hiroshi Ohtsu 11, Michio Tomura12, Nam H. Dang13, Yutaro Kaneko14, Kei Ohnuma1 & Chikao Morimoto1  \nCancer cells acquire malignant traits through epigenetic remodeling driven by inﬂammatory secretomes in the tumor microenvironment. However, how immune-derived inﬂammatory factors regulate cancer cell epigenetics remains poorly understood. Here, we show that IL-26 produced by tumor-speciﬁc type 17 T cells acts as a key mediator of epigenetic reprogramming associated with cancer malignancy. We identify selective accumulation of IL-26–expressing T cells in colorectal tumors resistant to immune checkpoint blockade therapy. IL-26 functions as a noncanonical cytokine by translocating into the nucleus of tumor cells, where it directly binds STAT1 and forms transcriptional complexes with NF-κB and AP-1. Nuclear IL-26 induces a transcriptionally active chromatin state characterized by BRD4and H3K27ac enrichment, resulting in upregulation of CXCL chemokines. This process promotes neutrophil inﬁltration and enhances immune evasion and tumor progression by suppressing CD8 + T cell responses. Together, these ﬁndings support a model in which tumor-speciﬁctype 17 T cells directly reprogram cancer cell epigenetics through IL-26, reshaping the tumor immune microenvironment to promote immune evasion.  \nBlockade of immune checkpoints such as programmed death-ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) axis induces CD8+ T cell activation, which plays a pivotal role in eradicating tumors, resulting in robust antitumor immune responses1. Among colorectal cancers (CRCs), mismatch repair-deﬁcient (MMRd) CRC is associated  \nwith a higher tumor neoantigen load and denser immune cell inﬁltration, suggesting a beneﬁt from immune checkpoint blockade (ICB) therapy2. However, immune status differs among MMRd CRCs, and >50% of patients experience resistance to ICB therapy3,4. In contrast, mismatch repair-proﬁcient and microsatellite-stable (MMRp) CRCs  \n1Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan. 2Atopy (Allergy) Research Center, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan. 3Laboratory of Cell Biology, Research Support Center, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan. 4Center for Immune Therapeutics and Diagnosis, Juntendo University Graduate School of Medicine, Tokyo, Japan. 5Department of Biofunctional Microbiota, Graduate School of Medicine, Juntendo University, Tokyo, Japan. 6Department of Human Pathology, Juntendo University School of Medicine, Tokyo, Japan. 7Department of Breast Oncology, Juntendo University School of Medicine, Tokyo, Japan. 8Department of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan. 9Department of Pathology, School of Medicine, Wakayama Medical University, Wakayama, Japan. 10Department of Immunological Diagnosis, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan. 11Faculty of Health Data Science, Juntendo University, Bunkyo-ku, Tokyo, Japan. 12Laboratory of Immunology, Faculty of Pharmacy, Osaka Ohtani University, Osaka, Tondabayashi, Japan. 13Division of Hematology/Oncology, University of Florida, Gainesville, FL, USA. 14Y’s AC Co., Ltd.,  \nChiyoda-ku, Tokyo 102-0074, Japan. e-mail: [t-ito@juntendo.ac.jp](t-ito@juntendo.ac.jp); [rhatano@juntendo.ac.jp](rhatano@juntendo.ac.jp)  \nhave a low mutational burden and ar","cbCaijIjNts8KSVv","https://ap.wps.com/l/cbCaijIjNts8KSVv","pdf",2810629,16,"English","# Background and clinical context\n## Immune checkpoint resistance in colorectal cancer\n## Tumor-elicited inflammation and neutrophil infiltration\n## Type 17 cytokines and epigenetic remodeling\n# IL-26 mechanism in tumor cells\n## Nuclear localization and STAT1 binding\n## Transcriptional complexes with NF-κB and AP-1\n## Chromatin activation and CXCL chemokine upregulation\n# Functional consequences\n## Neutrophil infiltration and CD8+ T cell suppression\n## Immune evasion and tumor progression model","[{\"question\":\"What is IL-26’s role in colorectal cancer immune evasion?\",\"answer\":\"IL-26 produced by tumor-specific type 17 T cells directly reprograms cancer cell epigenetics. It drives a nuclear transcriptional mechanism that increases CXCL chemokines and promotes neutrophil infiltration while suppressing CD8+ T cell responses, enabling immune evasion.\"},{\"question\":\"How does IL-26 act inside tumor cells mechanistically?\",\"answer\":\"IL-26 functions as a noncanonical cytokine by translocating into the nucleus of tumor cells. There it binds STAT1 and forms transcriptional complexes with NF-κB and AP-1, leading to a transcriptionally active chromatin state marked by BRD4 and H3K27ac.\"},{\"question\":\"Why is IL-26 associated with resistance to immune checkpoint blockade?\",\"answer\":\"IL-26–expressing type 17 T cells selectively accumulate in colorectal tumors that are resistant to immune checkpoint blockade therapy. This IL-26-driven pathway promotes immune-suppressive microenvironment features such as neutrophil infiltration and CD8+ T cell suppression.\"}]","IL-26-driven epigenetic remodeling promotes immune evasion in colorectal cancer | PDF",1790123378,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1f72e20f4680357f6e530aee35dcdc4f.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f67813835b1f7b8b3f1679dc2780dd56.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e10de62350d3da40478f679546cb227.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e422ba21f404120cc68c288e2df6588d.webp",980,1301]